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Skeletal and cardiac muscles play key roles in the regulation of systemic energy homeostasis and display
remarkable plasticity in their metabolic responses to caloric availability and physical activity. In this Perspec-
tive we discuss recent studies highlighting transcriptional mechanisms that govern systemic metabolism by
striated muscles. We focus on the participation of the Mediator complex in this process, and suggest that
tissue-specific regulation of Mediator subunits impacts metabolic homeostasis.Introduction
In the 21st century, obesity and type II diabetes mellitus have
becomeworldwide epidemics. The prevalence of these diseases
continues to rise as technologic innovation has decreased reli-
ance on physical activity for survival and allowed for easy access
to high-calorie food. Metabolic syndrome precedes type II dia-
betes in many patients, and is characterized by abdominal
obesity, hypertension, insulin resistance, and inflammation.
Consequently, metabolic syndrome carries an increased risk of
heart attack, stroke, and premature death (Malik et al., 2004).
Skeletal muscle and the heart play central roles inmetabolic syn-
drome and are regulators of total body mass and energy con-
sumption (Rolfe and Brown, 1997). Excess triglycerides, free
fatty acids, and glucose, coupled with physical inactivity, per-
turbs metabolism in skeletal and cardiac muscle. As striated
muscles adapt to increased substrate availability, systemic
metabolic homeostasis is altered, contributing to the onset of
obesity and diabetes.
Obesity and diabetes evoke a characteristic cardiac phenotype
knownas ‘‘diabetic cardiomyopathy’’ (Hamby et al., 1974) with an
underlying transcriptional basis associated with diminished car-
diac function (Battiprolu et al., 2010). Transcriptional regulation
of metabolic genes occurs through interactions of ligand-binding
nuclear receptors (NRs), transcriptional coregulators, chromatin
modifiers, and the Mediator complex among other factors (Burris
et al., 2013; Finck and Kelly, 2006; Mouchiroud et al., 2014).
Recent investigations have revealed that changes in metabolic
gene transcription in heart and skeletal muscle, induced by mus-
cle-specific manipulation of Mediator subunits, modulate sys-
temic metabolic disease (Baskin et al., 2014b; Chen et al., 2010;
Grueter et al., 2012; Lee et al., 2014). These studies imply that
metabolic transcriptional adaptations in muscle are not only a
consequence of metabolic disease, but also a potential disease
modifier. Herewe summarize theways inwhichmuscle transcrip-
tion affects whole-body energy homeostasis, and review the
tissue-specific roles of Mediator components in this process.
The Role of Muscle in Systemic Metabolic Homeostasis
Skeletal muscle comprises40% of total human body mass in a
healthy-weight individual (Rolfe and Brown, 1997). Together,skeletal muscle and the heart account for almost 30% of resting
energy consumption and nearly 100% of increased energy con-
sumption during exercise (Gallagher et al., 1998). Skeletal mus-
cle is heterogeneous and composed of slow and fast-twitch fiber
types, which differ in the composition of contractile proteins,
oxidative capacity, and substrate preference for ATP production.
Slow-twitch fibers display low fatigability, high oxidative capac-
ity, and a preference for fatty acids as substrate for ATP produc-
tion. Fast-twitch fibers have a higher fatigability, higher strength
of contraction, lower oxidative capacity, and a preference for
glucose as a substrate for ATP production through anaerobic
glycolysis (Bassel-Duby and Olson, 2006; Schiaffino and Re-
ggiani, 2011). Thus, fiber type composition of skeletal muscle
profoundly impacts systemic energy consumption (Figure 1).
Endurance or aerobic exercise increases mechanical and
metabolic demand on skeletal muscle, resulting in a switch
from a fast-twitch to a slow-twitch fiber type (Figure 1A).
Conversely, in obesity and diabetes, characterized by excess
caloric intake without increased metabolic demand, a slow-to-
fast fiber type switch occurs in muscle, which decreases oxida-
tive capacity (Mootha et al., 2003). Insulin resistance, a hallmark
of metabolic syndrome and diabetes, correlates with a higher
composition of fast-twitch myofibers (Simoneau et al., 1995).
Resistance training also impacts skeletal muscle metabolism
by increasing muscle mass and enhancing the oxidative and
glycolytic capacity of fast-twitch fibers (LeBrasseur et al.,
2011). Diabetic patients on a regimen of resistance training
have improved insulin sensitivity (Zanuso et al., 2010), and obese
patients subjected to resistance training develop increased lean
mass and a higher resting metabolic rate (Willis et al., 2012).
Exercise impacts systemic glucose and lipid homeostasis and
alters muscle fiber type composition, which is regulated at the
level of transcription.
Transcriptional Regulation of Metabolic Genes
in Striated Muscle
Transcriptional regulation of metabolic genes in muscle begins
with tissue-extrinsic signals such as peptides, steroid hormones,
and catecholamines, as well as tissue-intrinsic signals in-
cluding mechanical stretch, intracellular calcium, and nutrientCell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc. 237
Figure 1. The Role of Muscle Fiber Types in the Regulation
of Systemic Metabolism
(A) Slow-twitch myofibers have a high oxidative capacity and prefer fatty acids
as substrate for ATP production. Fast-twitch fibers have a lower oxidative
capacity and prefer glucose. Muscle fiber type can be altered by external and
internal factors. Exercise increases the number of slow-twitch fibers, thus
enhancing fatty acid utilization, while obesity increases fast-twitch fibers and
causes slow-twitch fibers to become insulin resistant. Muscle fiber type is
transcriptionally regulated, ultimately impacting systemic metabolism.
(B) Nuclear receptors, such as PPARs, ERRs, TRs, and Nur77 activate
transcription of genes involved in myofiber switching. PGC1a is a coregulator
and acts with PPAR, ERR, and TR to drive the switch from fast to slow fibers.
RIP140 and NCoR1 are corepresors for PPARs, ERRs, and TRs. TZDs, insulin
sensitizing drugs, reactivate PPAR in the setting of diabetes and obesity, which
can also lead to myofiber switching. PPAR, peroxisome proliferator-activated
receptor; ERR, estrogen-related receptor; TR, thyroid hormone receptor;
Nur77, orphan nuclear receptor NR4A1; PGC1a, peroxisome proliferator-
activated receptor gamma coactivator 1 alpha; RIP140, corepressor receptor-
interacting protein 140; NCoR, nuclear receptor corepressor; TZD, thiazolidi-
nediones.
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mediator of many of these signals and plays a critical role inmus-
cle metabolism by stimulating the transcriptional activity of two
key metabolic regulators: peroxisome proliferator-activated re-
ceptor alpha (PPARa) and peroxisome proliferator-activated re-
ceptor gamma coactivator 1 alpha (PGC1a) (Czubryt et al.,
2003). These factors, in turn, coordinate with others such as
GLUT4 enhancer factor (GEF), cAMP response element-binding
protein (CREB), and nuclear respiratory factor (NRF) to mediate
transcription of genes involved in fatty acid and glucose meta-
bolism (reviewed in Egan and Zierath, 2013).
During exercise, many signaling pathways are activated that
ultimately lead to transcriptional changes in muscle. For
example, increased intracellular calcium activates calcium/
calmodulin-dependent protein kinase II (CaMKII), mechanical238 Cell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc.stretch activates mitogen-activated protein (MAP) and c-Jun
N-terminal (JNK) kinases, and changes in NAD/NADH and
AMP/ATP ratios activate sirtuins and AMP-activated protein ki-
nase (AMPK), respectively (Egan and Zierath, 2013). As a result,
PPARa and PGC1a transcriptional activity is increased, mito-
chondrial biogenesis is induced, and fatty acid oxidation is
enhanced. Conversely, in metabolic syndrome, adiposity is
increased as energy supply outpaces demand. Circulating
glucose, triglycerides, and free fatty acids are increased, as
well as inflammatory mediators, insulin, leptin, and other adipo-
kines. Excess free fatty acids and inflammatory cytokines
released from adipose tissue macrophages disrupt insulin
signaling and lead to a decrease in heart and skeletal muscle
glucose utilization (Malik et al., 2004). Transcriptional regulation
of metabolic genes is essential for adaptation of striated muscle
to physiological challenges, and is predominantly regulated
by NRs.
Metabolic Control by NRs in Muscle
NRs are transcription factors that are activated by multiple li-
gands including lipids, steroids, retinoids, and hormones (Burris
et al., 2013). Many NRs are expressed in skeletal muscle and
heart and transcriptionally regulate various aspects of meta-
bolism including mitochondrial biogenesis, substrate utilization,
and fiber type switching (Fan et al., 2013; Huss and Kelly,
2004). NRs well studied in this regard are peroxisome prolifera-
tor-activated receptors (PPARs), estrogen-related receptors
(ERRs), thyroid hormone receptors (TRs), and Nur77 (Figure 1B).
PPARs are critical regulators of metabolic genes in striated
muscle (Madrazo and Kelly, 2008). PPARa is expressed in tis-
sues with a high capacity for fatty acid catabolism, such as heart
and skeletal muscle. When bound to long chain fatty acids or
eicosanoids, PPARa activates transcription of genes required
for fatty acid uptake and oxidation. The role of PPARa in muscle
and heart has been revealed using genetic mouse models.
Ppara-deficient mice developmyocardial lipotoxicity, and inhibi-
tion of fatty acid metabolism in these mice results in lethal hypo-
glycemia (Djouadi et al., 1998) (Table 1). PPARa activation also
robustly induces fatty acid utilization in human muscle cells
(Muoio et al., 2002). In transgenic mousemodels of skeletal mus-
cle (Finck et al., 2005) and cardiac-specific overexpression of
PPARa (Finck et al., 2002), skeletal muscle and the heart become
insulin resistant. In diabetic patients, insulin resistance enhances
PPARa activation in the heart resulting in altered cardiac meta-
bolism (Young et al., 2002), and PPARa activity is decreased in
the failing human heart (Lopaschuk et al., 2010).
PPARb/d, like PPARa, is activated by fatty acids derived from
triglycerides (Neels and Grimaldi, 2014). PPARb/d facilitates the
formation of oxidative muscle fibers through PGC1a activation
(Schuler et al., 2006), and its overexpression in skeletal muscle
causes a lean phenotype, mimicking exercise training (Wang
et al., 2004). While deletion of Pparb/d in cardiac muscle causes
lipotoxicity and progressive heart failure (Cheng et al., 2004), its
overexpression in the heart increases cardiac glucose meta-
bolism and protects the heart from ischemia-reperfusion injury
(Burkart et al., 2007) (Figure 1B). PPARb/d may be a beneficial
therapeutic target to combat metabolic syndrome given the
role of the PPARb/d-selective agonist GW501516 as a potential
exercise mimetic, although side effects of PPARb/d activation
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et al., 2013).
PPARg is enriched in adipose tissue, but also regulates meta-
bolism in striatedmuscle (Ahmadian et al., 2013). Global deletion
of Pparg causes lethality in mice, and deletion in the heart leads
to cardiac hypertrophy and dysfunction, although the metabolic
effects of Pparg deletion in the heart have not been evaluated
(Madrazo and Kelly, 2008). Cardiac overexpression of PPARg
causes dilated cardiomyopathy accompanied by increased car-
diac lipid and glycogen storage (Son et al., 2007). Interestingly, a
constitutively active form of PPARg expressed in skeletal muscle
and heart decreased intramuscular lipid accumulation, suscepti-
bility to insulin resistance and obesity, and induced a shift to
slow-twitch myofibers (Amin et al., 2010). Conversely, mice
with the deletion of Pparg in skeletal muscle developed insulin
resistance and increased adiposity (Hevener et al., 2003; Norris
et al., 2003) (Table 1). Mouse models of PPARg are useful tools
for understanding tissue-specific functions of PPARg, particu-
larly because PPARg is a therapeutic target for the management
of metabolic diseases (Burris et al., 2013).
TRs are NRs that activate and repress transcription. Thyroid
hormones activate TRs, and have long been known to play an
important role in metabolism (Tata, 2013). TRs regulate expres-
sion of myosin heavy chain isoforms, a determinant of striated
muscle contractility and fiber type, and ultimately energy sub-
strate preference (Mullur et al., 2014; Yu et al., 2000). Increased
TR transcriptional activity in muscle is accompanied by a switch
from fast- to slow-twitch fiber type (Salvatore et al., 2014)
(Figure 1B). Genetic models of TRs have also implicated TR in
cardiac metabolism and function (Esaki et al., 2004; Hyyti
et al., 2008; Kahaly and Dillmann, 2005; Pazos-Moura et al.,
2000) (Table 1). Indeed, decreased thyroid hormone activity
has been correlated with worsening heart failure, but efforts to
improve heart function with TR agonists have been unsuccessful
and are associated with adverse side effects (Burris et al., 2013).
To date most in vivo studies on TRs have utilized genetic models
with global TR gene disruption; however, TR isoforms have
unique expression patterns. Given their role in striated muscle
function and systemic metabolism, it will be important for future
studies to determine tissue-specific regulation and function of
TR isoforms (Flamant and Gauthier, 2013).
Orphan NRs, such as ERRs and Nur77, have no known natural
ligands. ERRa is abundantly expressed in tissues with high
metabolic and oxidative capacity, and its transcriptional activity
is highly dependent on coregulatory proteins, such as PGC1a
(Huss et al., 2004; Villena and Kralli, 2008). ERRa induces
expression of fatty acid metabolism genes in skeletal and car-
diac muscle, but regulates expression of metabolic genes in
other cell types as well (Gigue`re, 2008). Mouse gene deletion
studies have revealed a role for ERRa in regulation of cardiac en-
ergy metabolism and adaptation to pressure overload (Huss
et al., 2007; Huss and Kelly, 2004; Villena and Kralli, 2008).
ERRa is also important in muscle regeneration and recovery of
mitochondrial function in muscle after injury (LaBarge et al.,
2014). Global deletion of Errg is lethal due to impairment in peri-
natal cardiac function and cardiometabolic switching (Alaynick
et al., 2007). Overexpression of ERRg in skeletal muscle in-
creases exercise endurance as a result of fast-to-slowmuscle fi-
ber type switching (Narkar et al., 2011), and recently, ERRs wereshown to regulate muscle fiber type switching in cooperation
with PPARs through a muscle microRNA network (Gan et al.,
2013). The orphan NR Nur77 is also important in muscle fiber
type switching; it regulates expression of metabolic genes in
muscle (Pearen and Muscat, 2010). Nur77 knockout mice
develop skeletal muscle insulin resistance in response to a
high-fat diet (Chao et al., 2009), whereas overexpression of
Nur77 in muscle increases oxidative metabolism (Chao et al.,
2012). While additional NRs may be involved in muscle fiber
type switching, those more thoroughly studied are shown in
Figure 1B.
NR transcriptional activities are facilitated by transcriptional
coactivators, such as PGC1a, which promotes histone acetyla-
tion, binding to the Mediator complex, and recruitment of RNA
polymerase II (Pol II) to initiate transcription (Mouchiroud et al.,
2014; Wallberg et al., 2003). PGC1a was originally identified in
brown adipose tissue through its association with PPARg. It
functions in tissues with high oxidative capacity to regulate my-
ofiber switching, mitochondrial biogenesis, and expression of
fatty acid oxidation enzymes (Figure 1B) (reviewed in Chan and
Arany, 2014; Finck and Kelly, 2006; Lin et al., 2005). Overexpres-
sion of PGC1a in skeletal muscle causes a switch from fast to
slow muscle fiber type accompanied by resistance to fatigue
(Lin et al., 2002), and overexpression of PGC1a in the heart en-
hances mitochondrial biogenesis (Lehman et al., 2000).
Conversely, global deletion of Pgc1a decreases exercise capac-
ity and cardiac function, and disrupts cardiac metabolism (Arany
et al., 2005; Leone et al., 2005). Based on these and other
studies, it is evident that PGC1a-mediated NR activity is an
important regulator of striated muscle metabolism and function.
Indeed, PGCa1 expression is decreased in muscles of insulin-
resistant diabetic patients, and this is associated with decreased
expression of fatty acid oxidation genes (Chan and Arany, 2014;
Lin et al., 2005).
NR corepressors (NCoRs) are also important regulators of
transcription (Mouchiroud et al., 2014). The two most relevant
in the context of muscle metabolism and myofiber switching
are corepressor receptor-interacting protein 140 (RIP140) and
NCoRs. RIP140 was originally identified as a repressor of ERR
transcriptional activity, but it also inhibits PPAR and TR activity.
Mice with global overexpression of RIP140 present with
decreased mitochondrial gene expression, mitochondrial activ-
ity, cardiac hypertrophy, and early mortality (reviewed in Nautiyal
et al., 2013). NCoR also represses transcriptional activity of
PPARs, ERRs, and TRs. Consequently, deletion of Ncor in mus-
cle increases mitochondrial function and causes a switch from
fast- to slow-twitch muscle fiber type (reviewed in Mottis et al.,
2013) (Figure 1B).
Given their robust induction of metabolic gene transcription,
NRs are attractive drug targets for treatment of metabolic dis-
ease. Indeed, PPARawas identified as the target of the triglycer-
ide-lowering fibric acid derivative medications fenofibrate and
gemfibrozil, which are used to treat hypertriglyceridemia (Krey
et al., 1997). Thiazolidinediones (TZDs), also known as glita-
zones, are a class of drugs used in the treatment of diabetes.
TZDs are PPARg agonists and are currently the most potent in-
sulin-sensitizing drugs. They are, however, limited in their use by
cardiovascular side effects including increased incidence of
heart failure and myocardial infarction (Burris et al., 2013). SideCell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc. 239
Table 1. Mediator Subunits and Interacting Nuclear Receptors that Regulate Metabolism
Mediator Subunit
or NR Target Tissue (Organism, Driver) Phenotype Reference
MED1 skeletal muscle deletion (mouse,
MCK-Cre)
enhanced insulin sensitivity, improved
glucose tolerance on high-fat diet
Chen et al., 2010
MED1 liver deletion (mouse, Albumin-Cre) reduced hepatic steatosis on high-fat diet Jia et al., 2004
MED12 heart/muscle deletion (Drosophila,
Mef2-Gal4)
increased susceptibility to obesity Lee et al., 2014
MED13 heart/muscle deletion (Drosophila,
Mef2-Gal4)
increased susceptibility to obesity Lee et al., 2014
MED13 heart deletion (mouse, aMHC-Cre) increased susceptibility to obesity Grueter et al., 2012
MED13 heart transgenic (mouse, aMHC) enhanced lipid metabolism and insulin
sensitivity, leanness, decreased
susceptibility to obesity
Grueter et al., 2012;
Baskin et al., 2014b
MED15 global knockdown (C. elegans, RNAi) decreased fat storage Yang et al., 2006
MED23 liver deletion (mouse, Albumin-Cre) increased glucose and lipid metabolism
and insulin responsiveness
Chu et al., 2014
MED30 global missense mutation (mouse) mitochondrial dysfunction in heart
and heart failure
Krebs et al., 2011
CDK8 liver knockdown (mouse, tail vein
injection of adenovirus expressing
shRNA against CDK8)
hepatic steatosis Zhao et al., 2012
PPARa global deletion (mouse) etoxomir-induced cardiac lipotoxicity,
hypoglycemia, lethality
Djouadi et al., 1998
PPARa heart transgenic (mouse, aMHC) cardiac insulin resistance, diabetic
cardiomyopathy
Finck et al., 2002
PPARa skeletal muscle transgenic (mouse, MCK) skeletal muscle insulin resistance Finck et al., 2005
PPARb/d heart deletion (mouse, aMHC-Cre) lipotoxic cardiomyopathy Cheng et al., 2004
PPARb/d heart transgenic (mouse, aMHC) increased cardiac glucose metabolism,
hearts protected from ischemia-reperfusion
injury
Burkart et al., 2007
PPARb/d skeletal muscle deletion (mouse,
HSA-Cre)
increased number of fast muscle fibers
with reduced oxidative capacity, insulin
resistance, adiposity
Schuler et al., 2006
PPARb/d skeletal muscle transgenic (mouse, HSA) increased number of slow muscle fibers,
leanness, decreased susceptibility to
obesity, increased exercise endurance
Wang et al., 2004
PPARg heart transgenic (mouse, aMHC) dilated cardiomyopathy, increased cardiac
lipid and glycogen storage
Son et al., 2007
PPARg skeletal muscle deletion (mouse,
MCK-Cre)
glucose intolerant, insulin resistant,
increased adiposity
Hevener et al., 2003;
Norris et al., 2003;
PPARg muscle constitutively active transgenic
(mouse, HSA)
decreased intramuscular lipid
accumulation, decreased susceptibility to
obesity and insulin resistance, increased
number of slow muscle fibers
Amin et al., 2010
TRa global deletion of a1 (mouse) decreased muscle weight, increased
proportion of slow-twitch fibers
Yu et al., 2000
TRa/b global deletion of a1/b (mouse) decreased body and muscle weight,
increased proportion of slow-twitch fibers
Yu et al., 2000
TRa global knock-in mutation (mouse) decreased body weight, heart size, blood
pressure, cardiac glucose utilization
Esaki et al., 2004
TRb global knock-in mutation (mouse) increased cardiac glucose utilization Esaki et al., 2004
TRb heart dominant-negative b1 (mouse,
aMHC)
cardiac dysfunction, reduced substrate flux
through multiple pathways in the heart
Pazos-Moura et al., 2000;
Hyyti et al., 2008;
ERRa global deletion (mouse) impaired cardiac metabolism, cardiac
maladaptation to hemodynamic stress
and ischemia
Huss et al., 2007
(Continued on next page)
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Table 1. Continued
Mediator Subunit
or NR Target Tissue (Organism, Driver) Phenotype Reference
ERRa skeletal muscle deletion (mouse, MCK-Cre) impaired muscle regeneration and recovery
of mitochondrial function in muscle after
injury
LaBarge et al., 2014
ERRb/g skeletal muscle deletion (mouse, HSA-Cre) decreased exercise endurance Gan et al., 2013
ERRg global deletion (mouse) lethal, decreased embryonic cardiac
function, disruption of perinatal
cardiometabolic switching
Alaynick et al., 2007
ERRg skeletal muscle transgenic (mouse, HSA) increased exercise endurance, resistance
to diet-induced obesity
Narkar et al., 2011
Nur77 global deletion (mouse) high-fat-diet-induced skeletal muscle
insulin resistance, increased susceptibility
to obesity
Chao et al., 2009
Nur77 skeletal muscle transgenic (mouse, MCK) increased mitochondrial number and
function in skeletal muscle, improved
muscle performance
Chao et al., 2012
Summary of genetic models of Mediator subunits that display a metabolic phenotype, and genetic mouse models of nuclear receptors that affect stri-
ated muscle, some of which interact with Mediator subunits, as discussed in the text. MCK, muscle creatine kinase; aMHC, alpha myosin heavy chain;
HSA, human skeletal muscle actin.
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ture of NRs themselves, but could also be due to drug promiscu-
ity. In this regard, it will be critical to determine the tissue-specific
roles of the Mediator complex in regulating transcription in
response to modulation of various NRs.
The Mediator Complex
The interaction of NRs, transcriptional coactivators and core-
pressors, general transcription factors, and chromatin modifica-
tion complexes (collectively referred to as the pre-initiation com-
plex [PIC]) with RNA Pol II occurs through theMediator complex.
Mediator comprises a ubiquitous group of nuclear proteins that
regulate gene transcription through multiple mechanisms. First
discovered in yeast as an essential regulator of activator-
induced transcription (Flanagan et al., 1991), the Mediator com-
plex has been isolated from mammalian cells in active and inac-
tive forms. The core Mediator complex contains 26 subunits and
consists of three domains: the head, body, and tail (Taatjes,
2010). The CDK8 kinase submodule, consisting of four subunits,
acts as a transcriptional regulator of the core Mediator complex.
The kinase submodule represses the Mediator complex by allo-
sterically inhibiting RNA Pol II binding, but also activates TR-
dependent transcription by promoting Pol II recruitment to TR
target genes (Belakavadi and Fondell, 2010; Fondell, 2013)
(Figure 2). The Mediator complex is essential for PIC formation,
by interacting with all the components of the PIC to initiate
recruitment of RNA Pol II, resulting in activation of transcription
(Poss et al., 2013).
In human cells, the Mediator complex was first identified as a
TR coactivator (Fondell et al., 1996). MED1 (also called
TRAP220) was the first subunit identified and has since been
shown to directly and functionally interact with nearly all NRs
for which a ligand is known, including steroid and TRs, vitamin
D and retinoic acid receptors, and PPARs (Chen and Roeder,
2011; Fondell, 2013). The Mediator requires an open chromatin
conformation for binding and recruitment of RNA Pol II. In this re-gard, PGC1a has been shown to bind and recruit histone acetyl-
transferases, opening chromatin conformation, and facilitating
transcription of MEF2- and PPAR- regulated genes, likely
through a Mediator-dependent mechanism (Puigserver et al.,
1999). Given the significance of NRs in regulating metabolic
gene expression, it is essential to determine the role of Mediator
as it pertains to metabolic homeostasis.
Electron microscopy studies have demonstrated that the
Mediator binds to transcription factor activation domains and
subsequently changes conformation upon binding (Taatjes
et al., 2002). The conformation adopted by theMediator appears
to be distinct for different transcription factors. Such a mecha-
nismmay enable the Mediator to differentially regulate transcrip-
tion, depending upon transcription factor availability, possibly in
a tissue-specific manner. There is preliminary evidence support-
ing this hypothesis in studies investigating the role of MED23 in
different cell types (Balamotis et al., 2009). Because multiple
signaling pathways converge on transcription factors, which
are differentially regulated in a cell-specific manner, it is feasible
that the ultimate effect on the Mediator complex and resulting
gene expression is dependent on cell type and physiologic
context. One could also imagine a scenario in which tissue-spe-
cific transcription factors are activated and bound to Mediator
subunits, inducing a conformational change in Mediator and
subsequently exposing other Mediator subunits for binding by
additional transcriptional regulators.
Mediator-regulated transcription is not only controlled by
signaling pathways and their downstream action on transcription
factors, but also by posttranslational modifications (PTMs) on
Mediator itself. Although these studies are still in their infancy,
a number of phosphorylation sites have been identified on Medi-
ator subunits (Miller et al., 2012). Interestingly, MED1 phosphor-
ylation by extracellular signal-regulated kinase (ERK) leads to
enhanced transcription of TR-regulated genes (Belakavadi
et al., 2008). Additionally, MED13/MED13L are targeted for
degradation through ubiquitination by SCF-Fbw7, whichCell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc. 241
Figure 2. The Mediator Complex
The transcriptionally active core Mediator complex consists of the head (blue),
body (red), and tail (light green) domains, and the relative location of the
subunits is depicted. The CDK8 kinase submodule (yellow) reversibly asso-
ciates with the core complex and regulates Mediator transcriptional activity.
The Mediator complex regulates transcription by interacting with nuclear re-
ceptors, general transcription factors (GTFs), RNA polymerase II (Pol II), and
enhancers. TR, thyroid hormone receptor; PPARs, peroxisome proliferator-
activated receptors.
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complex (Davis et al., 2013). It is likely that other PTMs regulate
Mediator subunits, and of particular interest are those generated
by metabolic pathways. For example, palmitoylation and/or
O-linked beta-N-acetylglucosamine (O-GlcNAc) modification of
Mediator subunits could enhance or inhibit interactions with
other transcription factors and coactivators/corepressors (Oz-
can et al., 2010). Acetylation, a more commonly studied meta-
bolic PTM, not only regulates histone architecture and access
to DNA, but also NR activity, and could also regulate Mediator
activity (Lu and Thompson, 2012; Wang et al., 2011). While
very little is known, it will be interesting to investigate the role
of metabolically driven PTMs on Mediator activity, particularly
as a regulator of tissue- and cell-specific transcriptional regula-
tion. We suggest that metabolic PTMs and regulation of the
Mediator complex are intimately tied to the metabolic demand
of specific tissues.
In addition to being directly modified, Mediator components
may also posttranslationally modify transcription factors. For
example, the kinase CDK8, a component of the kinase submod-
ule of the Mediator complex, was shown to phosphorylate the
transcription factor sterol regulatory element binding protein242 Cell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc.(SREBP-1), leading to its ubiquitination and degradation, conse-
quently decreasing lipogenesis (Zhao et al., 2012). PTMs of the
Mediator complex, and modification of other transcriptional
components by the Mediator, adds another layer of complexity
to the regulation of transcription. These studies further support
the hypothesis that Mediator components are regulated, and
perhaps function, in a tissue-specific manner.
Metabolic Functions of Mediator Components in Muscle
The Mediator complex is required for normal cellular function,
and genetic mutations in components of the Mediator complex
have been implicated in a number of diseases. Several Mediator
subunits are directly involved in the development or progression
of cancer (Spaeth et al., 2011), and nearly everyMediator subunit
is dysregulated in some type of cancer (Schiano et al., 2014a).
Mediator subunits have also been implicated in neurodevelop-
mental disorders and cardiovascular defects and diseases
(Grueter, 2013; Napoli et al., 2012; Schiano et al., 2014b). Addi-
tionally, MED1, MED23, MED25, MED15, MED12, and MED13
play key roles in regulating tissue and systemic metabolic ho-
meostasis (Grueter, 2013; Jia et al., 2004; Napoli et al., 2012)
(summarized in Table 1). The Mediator components that alter
systemic metabolism in a muscle-specific manner are of partic-
ular interest (Figure 3).
In metazoans, Mediator components are expressed ubiqui-
tously throughout embryonic development and adulthood
(Poss et al., 2013). Genetic deletion of Med1 (Zhu et al., 2000),
Med24 (Ito et al., 2002), Cdk8 (Westerling et al., 2007), or
Med12 (Hong et al., 2005) in mice results in embryonic or preim-
plantation lethality. However, mice with skeletal muscle-specific
deletion of Med1 are viable. Female Med1 muscle knockout
mice are resistant to high-fat-diet-induced obesity and have
enhanced insulin sensitivity (Chen et al., 2010). These mice dis-
played an increase in mitochondrial gene expression and mito-
chondrial content of fast-twitch muscle, which also correlated
with fast-to-slow myofiber switching. This could account for
the improved insulin sensitivity in the setting of caloric excess.
As mentioned above, patients with diabetes showed decreased
oxidative capacity in muscle, which is suggestive of a slow- to
fast-twitch fiber type switch. The inability of TR to activate tran-
scription of fast-twitch genes in the absence of MED1 may ac-
count for a slow fiber type switch. Therefore, MED1may function
specifically in muscle to control whole-bodymetabolism through
its influence on muscle fiber type composition. While the role of
MED1 in diabetic patients is currently unknown, it will be of ther-
apeutic interest to investigate the role of Mediator subunits in
regulation of metabolic diseases.
Metabolic alterations in heart failure have been studied exten-
sively and are likely transcriptionally regulated, perhaps through
theMediator complex (Lopaschuk et al., 2010). Flux through cre-
atine kinase alters the phosphocreatine:ATP ratio, which leads to
increased substrate demand. The heart meets this demand by
increasing glucose utilization, ultimately shifting away from fatty
acids as the main energy source (Doenst et al., 2013). Corre-
sponding myosin switching occurs, with aMHC decreasing in
abundance as bMHC increases, in addition to a reversion to a
fetal metabolic gene profile (Razeghi et al., 2001). Underlying
gene expression changes include downregulation of PGC1a-,
PPARa-, and TR- regulated genes. Because NRs interact with
Figure 3. Mediator Subunits Alter Systemic
Metabolism in a Muscle-Specific Manner
Perturbations of MED13 and MED30 in the heart
alter metabolism. Overexpression of MED13 in the
heart causes leanness, and loss of MED13 in the
heart increases susceptibility of obesity and dia-
betes. Loss-of-function mutations in MED30 lead
to altered substrate availability, heart failure, and
death. Loss of MED1 in muscle causes a fast-to-
slow muscle fiber type switch, which enhances
insulin sensitivity and protects against obesity.
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complex are likely involved in regulation of cardiac metabolism
that occurs in heart failure, although this has not yet been inves-
tigated.
MED30 controls PGC1a-mediated expression of metabolic
genes. Mice with a loss-of-function mutation in Med30 die
from severe heart failure characterized by myocardial fibrosis,
necrosis, and impaired contractility (Krebs et al., 2011). Heart
failure progressed after weaning Med30 mutant mice due to
mitochondrial dysfunction in the heart. Progressive downregula-
tion of PGC1a and many oxidative phosphorylation and electron
transport genes was observed post weaning. These changes
suggested that altered substrate availability, which occurs with
changes in diet post weaning (from a high- to a low-fat diet),
could be responsible for altered gene expression and mitochon-
drial dysfunction. Indeed, Med30 mutant mice weaned onto a
ketogenic diet, which is similar to breast milk in fat content, sur-
vived longer and showed partial restoration of mitochondrial
gene expression (Krebs et al., 2011). While mutations in Med30
severely affect cardiac function and cardiac metabolism,
Med30mutant mice did not display a detectable skeletal muscle
phenotype. These results suggest that MED30 and possibly
other Mediator components could have tissue-specific roles.
Alternatively, the presence of other tissue-specific nuclear pro-
teins that interact with Mediator may be responsible for the car-
diac phenotype in Med30 mutant mice.
MED13 is a component of the kinase submodule of the Medi-
ator complex, which regulates Mediator activity. Studies in our
laboratory identified MED13 as a regulator of systemic meta-
bolism (Baskin et al., 2014b; Grueter et al., 2012). Overexpres-
sion of MED13 specifically in the heart led to a striking metabolic
phenotype in which mice were resistant to obesity and main-
tained insulin sensitivity when placed on a high-fat diet (Grueter
et al., 2012). In contrast, mice with cardiac-specific deletion of
Med13 had increased susceptibility to obesity and diabetes
(Grueter et al., 2012). We also demonstrated that Med13 defi-
ciency in striated muscles results in a similar phenotype in
Drosophila (Lee et al., 2014). However, the potential influenceCell Metabolism 21of MED13 in mammalian skeletal muscle
on systemic energy homeostasis is
currently under investigation.
MED13 is a target of microRNA-208a
(miR-208a), a cardiac-specific microRNA
that is critically important in myosin fiber
type switching in response to cardiac
stress (van Rooij et al., 2007). As in
MED13 cardiac transgenic mice, wild-type (WT) mice treated with an inhibitor of miR-208a became
lean and resistant to diet-induced obesity, and cardiac MED13
levels were increased (Grueter et al., 2012). Given the tissue-
specific expression of some miRs, and the therapeutic potential
of anti-miRs, MED13, and perhaps other Mediator components,
are attractive anti-miR targets to combat obesity (Olson, 2014;
Rottiers and Na¨a¨r, 2012). However, much more still needs to
be understood about the Mediator complex in order to unlock
its therapeutic potential.
Other components of the Mediator complex have been impli-
cated in the regulation of tissue-specific and systemic meta-
bolism. CDK8 suppresses lipogenesis by phosphorylating and
inhibiting SREBP-1 in the liver (Zhao et al., 2012). A separate
study demonstrated that MED17 is required for liver X receptor
(LXR)-dependent regulation of SREBP-1, thus activating hepatic
lipogenesis (Kim et al., 2014). Yet another study demonstrated
that MED15 is required for SREBP-1 activation of lipogenic
target genes in nematodes (Yang et al., 2006). MED1, MED14,
and MED23 are required for adipocyte development, and are ul-
timately involved in lipid metabolism as well (Chu et al., 2014;
Zhang et al., 2013). Interestingly, the nuclear corepressor
RIP140 interacts with CDK8 to regulate gene expression during
fibroblast-adipocyte differentiation (Nautiyal et al., 2013). One
function of the Mediator complex in muscle may be to inhibit
transcription of PPAR-activated genes, which could result in
release of molecular signals that modulate lipid metabolism in
distant tissues, implicating Mediator in the suppression of dia-
betes and obesity. We consider it important to identify other
Mediator subunits that modulate muscle and systemic meta-
bolism, given the broad systemic metabolic effect of manipula-
tion of Mediator components in only one tissue.
Mediator, Myokines, and theControl of Systemic Energy
Homeostasis
The mechanism(s) whereby nuclear proteins in the heart and
muscle can mediate metabolic changes in distant tissues is a
clinically relevant and ongoing topic of investigation. It is likely
that the Mediator plays a role in this process as evidenced by, February 3, 2015 ª2015 Elsevier Inc. 243
Figure 4. Proposed Roles for Mediator in Regulating Secreted
Factors and Systemic Metabolism
Secreted factors released from adipose tissue and liver regulate skeletal and
cardiac muscle metabolism, and many factors are released from heart and
muscle that exert feedback on these tissues. While the role of Mediator in
regulating secreted factors has not yet been investigated, it is highly likely that
Mediator is involved in this process. See text for discussion.
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diet-induced obesity (Grueter et al., 2012). We have recently
demonstrated, using heterotypic parabiosis, that circulating/
secreted factors control leanness in transgenic mice with car-
diac-specific MED13 overexpression (TG) (Baskin et al.,
2014b). WT mice from WT-TG heterotypic parabiotic pairs
gained less weight over time than their WT-WT isotypic parabi-
otic controls. Furthermore, metabolic rates in liver and adipose
tissue from WT mice subjected to heterotypic parabiosis were
significantly elevated, to the same extent as in TG mice. There-
fore, circulating factors within the systemic milieu of TG mice,
perhaps secreted by the heart, are responsible for enhanced
metabolic rate and leanness (Baskin et al., 2014b). We also iden-
tified wingless (wg) and armadillo as muscle-secreted proteins in
Drosophila that were necessary and sufficient to suppress fat
accumulation, and wg overexpression rescued the obese
phenotype inMed13 knockout flies (Lee et al., 2014). These find-
ings suggest that the heart and skeletal muscle produce
signalingmolecules that increasemetabolic rate of distal tissues,
and that this is regulated by Mediator.
There are other examples of secreted proteins that modulate
systemic metabolism and facilitate inter-organ communication,
and perhaps future studies will address the role of Mediator in
secretion of these factors (Figure 4). The adipokine leptin is the
most well-known adipose-derived hormone that regulates fat
storage (Halaas et al., 1995). Adiponectin, a hormone released
by adipose tissue, also acts on muscle to stimulate fatty acid
oxidation, and acts on liver to suppress gluconeogenesis (Kado-
waki et al., 2006). Other adipokines that affect systemic meta-
bolism include adipsin, resistin, and secreted frizzled-related
protein 5 (SFRP5) (Deng and Scherer, 2010). Insulin-like growth
factor 1 (IGF-1) and fibroblast growth factor 21 (FGF-21) also
regulate systemic metabolism and are secreted from adipose
tissue and liver, thus acting as adipokines and hepatokines (Ste-
fan and Ha¨ring, 2013).
Similar to adipokines, myokines are factors secreted from
muscle that act in an autocrine and/or paracrine manner (Peder-
sen and Febbraio, 2012; Weigert et al., 2014). Interleukin 6 (IL-6),
released from muscle with exercise, was the first classified my-
okine (Pedersen et al., 2004). IL-6 has been investigated in many
experimental settings and has tissue-specific effects (reviewed
in Pal et al., 2014), although it seems to play a role in glucose
and fatty acid metabolism inmuscle and other organs acutely af-
ter exercise (Mun˜oz-Ca´noves et al., 2013). Myostatin also regu-
lates glucose metabolism, and myostatin-deficient mice are
resistant to diet-induced obesity (Huang et al., 2011). Other my-
okines with roles in systemic metabolism include angiopoietin-
like protein 4 (ANGPTL4) (Mattijssen and Kersten, 2012), IL-15,
irisin, FGF-21 (reviewed in Pedersen and Febbraio, 2012), and
meteorin-like protein (Rao et al., 2014). GDF11 is another impor-
tant circulating factor that has beneficial effects on multiple tis-
sues, and it has most recently been shown to act as a ‘‘rejuve-
nating’’ factor by improving muscle function in old mice (Sinha
et al., 2014).
Cardiokines are factors secreted from the heart, although few
have been identified to date (Doroudgar and Glembotski, 2011;
Shimano et al., 2012). Unlike many of the known myokines,
most cardiokines identified act in an autocrine manner to regu-
late cardiac function and response to stress. For example, folli-244 Cell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc.statin-like 1 is antiapoptotic, and heat shock protein 20
(Hsp20) regulates angiogenesis in the heart. Thrombospondin
4 (TWEAK), mesencephalic astrocyte-derived neurotrophic fac-
tor (MANF), and the fibroblast growth factors FGF-21 and FGF-
23 regulate cardiac hypertrophy (Shimano et al., 2012), and
FGF-21 and IGF-1 are cardiokines that act in an autocrine
manner to regulate cardiac metabolism (Brahma et al., 2014;
Kajstura et al., 2001). Perhaps the only cardiokines known to
regulate systemic metabolism are atrial natriuretic peptide
(ANP) and B-type/ventricular natriuretic peptide (BNP), which
lead to browning of white adipose tissue (Bordicchia et al., 2012).
There are also examples of non-protein circulating factors that
act on distant tissues. For example, mice lacking adipose fatty
acid binding proteins FABP4 and FABP5 revealed a ‘‘lipokine’’
(C16:1n7-palmitoleate), secreted by adipocytes that acts on liver
and skeletal muscle, rendering mice resistant to metabolic syn-
drome (Cao et al., 2008). Along these same lines, PGC1a was
recently shown to regulate themetabolicmyokine b-aminoisobu-
tyric acid (BAIBA). Consequently, BAIBA induced a browning
phenotype in white adipose tissue (Roberts et al., 2014). Addi-
tionally, metabolic substrates, products, and intermediary me-
tabolites can act as ‘‘metabokines.’’ Indeed, altered substrate
flux has been suggested to regulate systemic metabolism
through cross-talk between heart and liver in the setting of hyper-
trophic cardiomyopathy (Baskin et al., 2014a; Magida and Lein-
wand, 2014). These discoveries are surely the tip of the iceberg
in deciphering inter-organ communication driven by Mediator
regulation of secreted factors, particularly the most recent class
of factors dubbed ‘‘myometabokines’’ (Weigert et al., 2014).
Questions for the Future
Investigation of Mediator components in muscle tissue is a
developing field that can potentially reveal novel molecules
and pathways that regulate metabolism. Deletion or overexpres-
sion of Mediator components in heart and skeletal muscle
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NR-regulated genes. Many of these genes are also regulated in
muscle in response to heart failure, obesity, and diabetes, indi-
cating that transcriptional manipulation by the Mediator in mus-
cle may possibly modulate systemic metabolism. Regulation of
metabolic homeostasis by secreted factors may likely be
controlled by Mediator in a tissue-specific manner as well. The
interaction between Mediator components, muscle-specific
transcription factors, NRs, coregulators, and other factors may
explain the systemic effects of tissue-specific manipulation of
ubiquitous Mediator components.
Our understanding of the Mediator complex has developed
quite rapidly, including the identification of Mediator compo-
nents, the structures of various subunits, and its general role in
transcription. These studies are just the beginning as we trans-
late what we know from in vitro studies to the role of theMediator
in specific tissues in vivo. Based on the studies we reviewed
here, it is evident that theMediator complex is an important regu-
lator of metabolism and plays a significant role in striated mus-
cle. We speculate that modulation of other Mediator compo-
nents in muscle will likely affect systemic metabolism.
NRs are prominent regulators of metabolism and muscle fiber
type, and recent evidence suggests that NRs interact with Medi-
ator components to regulate transcription (Chen and Roeder,
2011; Fondell, 2013). NRs are regulated by a variety of physio-
logical stimuli including exercise, and therefore it is logical to pre-
sume that the Mediator complex is regulated in a similar manner.
There are no known instances of regulation of Mediator with ex-
ercise, and to date, only a few studies on Mediator in muscle
have been reported (Figure 3). Future studies should focus on
how the Mediator complex is regulated in striated muscle under
homeostatic conditions and in response to various physiological
stimuli, such as exercise and metabolic and nutrient stress (e.g.,
fasting or different diets). It will also be of interest to determine
the role of Mediator components using gain- and loss-of-func-
tion mouse models.
Of course, many questions remain unanswered regarding the
regulation of the Mediator complex itself. MED13, a regulator of
systemic metabolism, is inhibited by miR-208a, and perhaps
other Mediator components follow suit. Indeed, in a screen for
target genes, several miRs have been shown to regulate the
expression of Mediator components in an embryonic stem cell
line (Davis et al., 2012). Additionally, miR-146, miR-1, and miR-
205 were shown to bind and regulate MED1 expression in sper-
matogonia, cancer cells, prostate cells, and trophoblasts,
respectively (Hulf et al., 2013; Huszar and Payne, 2013; Jiang
et al., 2014; Mouillet et al., 2010). Because MED1 seems to be
regulated by multiple miRs, perhaps in a cell-specific manner,
it will be important to determine the endogenous role of MED1
in these cell types. Furthermore, it will be interesting to extend
these findings in vivo.
Finally, human mutations in Mediator subunits have been
associated with developmental disorders, cardiovascular dis-
eases, and cancer (Grueter, 2013; Napoli et al., 2012; Schiano
et al., 2014b). Genetic mutations of Mediator components have
not been directly linked to metabolic diseases; however, it is
likely that genetic variants could disrupt Mediator-NR interac-
tions causing adverse metabolic consequences. Perhaps
genome-wide association studies (GWASs) can provide cluesabout possible genetic mutations in Mediator subunits underly-
ing metabolic diseases. However, it may very well be the case
that the interaction with NRs, which facilitate transcriptional ac-
tivity of the Mediator, is most important in the context of meta-
bolic regulation by the Mediator complex.
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